Clinical trials: Palmo-plantar Psoriasis
Palmoplantaris Pustulosis
A Placebo-Controlled Double-Blind Study on the Safety and Efficacy of Etanercept in Palmoplantar Pustulosis
Palmoplantar pustulosis (PPP) is a chronic recurrent skin condition characterized by the presence of pustules, erythema and hyperkeratosis on palms and soles.
- Trial name
- NCT00353119
- Testing
- Etanercept
- Where
- 3 sites in Canada
- Volunteers
- 15 people
- Sponsor
- Innovaderm Research Inc.
Palmo-plantar Psoriasis
Apremilast in Palmo-Plantar Psoriasis
This study will compare the safety and efficacy of Apremilast 30mg to placebo in subjects with moderate to severe plaque psoriasis involving palms and/or soles.
- Trial name
- NCT02400749
- Testing
- Apremilast
- Where
- 11 sites in United States, Canada
- Volunteers
- 100 people
- Sponsor
- Innovaderm Research Inc.
Scalp Psoriasis, Pustular Palmo-plantar Psoriasis
IL-17 Role in Variants of Psoriasis
The goal of this project is to study some mechanisms involved in the dysregulation of the immune system observed in the skin of subjects with psoriasis.
- Conditions
- Scalp Psoriasis, Pustular Palmo-plantar Psoriasis, Non-pustular Palmo-plantar Psoriasis, Elbow Psoriasis
- Trial name
- NCT02078297
- Where
- Canada
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Innovaderm Research Inc.
Palmo-Plantar Pustular Psoriasis, Palmo-Plantar Pustulosis
Safety and Efficacy of Ustekinumab in Patients With Palmo-Plantar Pustular Psoriasis or With Palmo-Plantar Pustulosis
This study will provide data on sasety and efficacy of Ustekinumab in patients suffering from Palmo-Plantar Pustular Psoriasis (PPPP) or Palmo-Plantar Pustulosis(PPP)
- Trial name
- NCT01091051
- Testing
- Ustekinumab
- Where
- 8 sites in Canada
- Volunteers
- 33 people
- Sponsor
- Innovaderm Research Inc.
Psoriasis
Efficacy of Alitretinoin Treatment in Patients With Pustular Form of Psoriasis
The main purpose of this study is to demonstrate the improvement in the skin condition rate of patients receiving alitretinoin compared to patients receiving placebo.
- Trial name
- NCT01245140
- Testing
- alitretinoin
- Where
- 8 sites in France, Germany and 2 more
- Volunteers
- 33 people
- Sponsor
- Stiefel, a GSK Company